-

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference

SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today that James Rolke Revelation’s Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference on Tuesday, March 18, 2025 at 10:00 a.m. PT in Dana Point, CA.

The fireside chat will be webcast live here and available on our Investors section of Revelation Biosciences website, www.RevBiosciences.com, after the meeting.

Investors who wish to schedule a meeting with Revelation’s management during the conference should contact their Roth representative.

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease.

For more information on Revelation, please visit www.RevBiosciences.com.

Contacts

Company Contacts
Mike Porter
Investor Relations
Porter LeVay & Rose Inc.
Email: mike@plrinvest.com

Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com

Industry:

Revelation Biosciences, Inc.

NASDAQ:REVB
Release Versions
English
$Cashtags
$REVB
Hashtags
#AKI
#CKD
#GEMINI
#REVB
#REVBIOSCIENCES

Contacts

Company Contacts
Mike Porter
Investor Relations
Porter LeVay & Rose Inc.
Email: mike@plrinvest.com

Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com

Social Media Profiles
REVB LinkedIn
REVB X
More News From Revelation Biosciences, Inc.

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its financial results for the three and six months ended June 30, 2025. Corporate Highlights Completed dosing of patients in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Received gross proceeds of $4 million from public offering in May 2025 "The Revelation team con...

Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research

SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (Nasdaq: REVB) the “Company” or “Revelation”) a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today congratulates its former chairman and shareholder, George Tidmarsh, MD, PhD, who has been selected to head the FDA Center for Drug Evaluation and Research. “George was the chairman of the board of our company, Revelation Biosciences, Inc., as well as one of the founders,” said James Rolke, Pres...

Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today announced dosing has been completed for the PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). As planned, a total of 5 cohorts were enrolled at 3 cl...
Back to Newsroom